REPORTS OF several independent clinical trials have attested to the benignity and to the antigenic potency of the live attenuated vaccine derived from the Jeryl Lynn strain of mumps virus.1-8 The present study was undertaken primarily to provide an independent laboratory evaluation of the serologic response to this vaccine.
As reported previously, the antibody response following natural mumps far exceeded that observed following immunization.2 In the present study, however, the rate of successful immunizations and the antibody titers observed four weeks following the administration of vaccine were both somewhat lower than had been reported previously by other workers.1,3,7 Vaccinees who were tested at five weeks following immunization, however, were found to have higher antibody titers and a higher rate of successful immunization than those who were tested at four weeks. In addition, some of the vaccinees who had little or no detectable antibody at four weeks were
Brunell PA, Brickman A, Steinberg S. Evaluation of a Live Attenuated Mumps Vaccine (Jeryl Lynn): With Observations on the Optimal Time for Testing Serologic Response. Am J Dis Child. 1969;118(3):435–440. doi:10.1001/archpedi.1969.02100040437004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: